SOHO Insider 2025 Print Issue July/August
The July/August issue features an editorial by Jerry Radich, MD, a feature article on radiotherapy in blood cancers, and an Interview with Alice
Soho Print
Past Issues
News
SOHO 2025
AI is in the spotlight at SOHO 2025
Artificial intelligence (AI) has seen a staggering influx of investment across nearly every sector, and hematologic oncology is no exception. While some may
EHA 2025
Lymphoma
Indolent B-Cell Lymphomas
Meetings / Conferences
Marek Trneny, MD, discusses phase 3 inMIND study
Dr. Trněný, a professor of medical oncology at Charles University Hospital in Prague, discusses results from the phase 3 INMIND study.
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Oral decitabine and cedazuridine combo shows promise as post-HSCT option
New findings published in The Lancet Haematology suggest that ASTX727, a fixed-dose, fully oral combination of decitabine and cedazuridine, could be a potential
Leukemia
Chronic Lymphocytic Leukemia
News
Does CLL arise through a multiclonal selection process?
New findings published in the journal Haematologica suggest that the genesis of chronic lymphocytic leukemia (CLL) involves competition among multiple B-cell clones with
Leukemia
Chronic Lymphocytic Leukemia
News
SOHO Insider Podcast
SOHO Insider leukemia podcast with Drs. O’Brien and Coombs
Listen to Susan O’Brien, MD, professor of medicine, and Catherine C. Coombs, MD, associate professor of medicine, both of the Chao Family Comprehensive
Multiple Myeloma
Dr. Shulman discusses US cancer surveillance challenges
Lawrence N. Shulman, MD, a medical oncologist at the University of Pennsylvania’s Abramson Cancer Center, discussed US cancer surveillance challenges in a recent
Multiple Myeloma
New blood test diagnoses multiple myeloma noninvasively
A next-generation blood test is able to diagnosis and monitor multiple myeloma (MM) and its precursor conditions by utilizing single-cell sequencing to profile
News
New AI tool ‘DeepHeme’ improves blood cancer diagnosis
A new artificial intelligence (AI)-powered diagnostic tool, DeepHeme, is able to perform individual cell classifications with an accuracy comparable to human experts, according
